DP031 | PROGNOSTIC IMPACT OF HIGH-RISK MUTATIONS IN SECONDARY AML TREATED WITH CPX-351: A FOCUS ON MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL

Background: Acute Myeloid Leukemia (AML) is a heterogeneous disease driven by somatic mutations. The ELN 2022 classification designated several mutations (e.g., TP53, ASXL1, SRSF2) as adverse with conventional chemotherapy. However, their prognostic significance may differ with newer treatments lik...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	C. Riva, P. Minetto, S. Nicoletta, R. Romei, M. Chies, G. Zecchetti, E. Maio, Y. Azzanelli, N. Colombo, S. Rosellini, A. Parodi, E. Tedone, E. Carminati, F. Puglisi, C. Nurra, G. Fugazza, P. Nozza, M. Cea, R.M. Lemoli, F. Guolo
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12795